EMG
SWTX

ETF Managers Group’s SpringWorks Therapeutics SWTX Stock Holding History

ETF Managers Group’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,681
Closed -$400K – 817
2022
Q2 		$400K Buy
+15,681
New +$573K 0.01% 552

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

ETF Managers Group's SWTX Position: Q3 2022 in Review

ETF Managers Group sold out of SpringWorks Therapeutics (SWTX) in Q3 2022, closing a stake of 15,681 shares — an estimated $400K sold.

ETF Managers Group first reported a position in SWTX in Q2 2022 and held it in 1 quarter. The position peaked at $400K in Q2 2022. 148 funds tracked by Wall St. Rank hold SWTX as of Q3 2022.

  • ETF Managers Group reported no remaining SpringWorks Therapeutics position as of Q3 2022 after selling out during the quarter.
  • ETF Managers Group sold 15,681 SpringWorks Therapeutics shares in Q3 2022, an estimated $400K.
  • ETF Managers Group first reported a position in SpringWorks Therapeutics in Q2 2022 and held it in 1 quarter.
  • ETF Managers Group's SpringWorks Therapeutics position peaked at $400K in Q2 2022.
  • 148 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2022.

Based on ETF Managers Group's 13F filing for Q3 2022, filed 14 Nov 2022.